Navigation Links
Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care
Date:9/24/2008

FDA Expert on Pharmacogenomics Offers a Prescription for Progress

WATERBURY, Conn., Sept. 24 /PRNewswire/ -- The Connecticut State Medical Society is joining with Genomas(R), a biomedical company advancing DNA-guided medicine and personalized healthcare, to co-sponsor a symposium -- DNA-Guided Medicine and the Path to Personalized Health Care -- being held today at the Society's annual meeting. Hartford Hospital is providing continuing medical education credits for physicians attending the meeting.

Lawrence J. Lesko, Ph.D., Director of the Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, will discuss FDA Initiatives in Personalized Medicine: Advancing Individualized Drug Therapy.

Dr Lesko commented: "The U.S. Department of Health and Human Services and the FDA have prioritized personalized medicine as one of their mission goals for public health. I am glad to participate in this event with the Connecticut Medical Society, Hartford Hospital and Genomas to bring these initiatives to physicians who are in an important position to implement them in their clinical practice. Connecticut is poised to become one of the national leaders in adoption of personalized medicine, and I am thrilled to join ranks with these local efforts as exemplary to improving the healthcare system as a whole."

Gualberto Ruano, M.D., Ph.D., President and CEO of Genomas, will speak about Progress Towards DNA-Guided Medicine in Clinical Practice: Case Studies in Cardiology and Psychiatry. Examples in these two therapeutic areas include statins and atypical antipsychotics.

Dr. Ruano commented: "We are privileged to partner with the Connecticut State Medical Society to convene the physicians in our state for this forum. The presence of the FDA is an indication of the national impact of the programs in DNA-Guided Medicine that Genomas has spearheaded in Connecticut with Hartford Hospital and the Hospital of Central Connecticut. Together, we are bringing personalized healthcare to our patients today, and setting the pathway to utilization of DNA-Guided Medicine as the standard of care in cardiovascular and psychiatric clinical practice."

ABOUT GENOMAS

Genomas Inc. is a biomedical company advancing DNA-guided medicine and personalized healthcare. The company develops revolutionary PhyzioType(TM) Systems for DNA-guided diagnosis and prevention of metabolic disorders induced by drugs in cardiovascular and psychiatric medicine. PhyzioType Systems are designed to provide physicians with the unprecedented capability to select for each patient the safest drug treatment to enhance compliance. Genomas is located in Hartford, CT on the campus of Hartford Hospital. For more information, please visit http://www.genomas.net

ABOUT PHYZIOTYPE CLINICAL MANAGEMENT SYSTEMS

PhyzioType Systems are composed of an ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by a biomathematical algorithm in order to convey to physicians predicted comparisons of side effect risk among drugs for the individual patient. To date, Genomas has secured $3.1 million from NIH Small Business Innovation Research (SBIR) for PhyzioType System product development.


'/>"/>
SOURCE Genomas Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Connecticut Technology Council to Recognize Fast Growing Technology Companies
2. Connecticut BioBus Travels to State Capitol on April 24 for Tours and Experiments with Visiting Students
3. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
4. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
5. NC State engineers discover nanoparticles can break on through
6. Department of Justice Provides States With Funding for Testing in Postconviction Cases
7. Orange Coast Urology Offers Advanced In-Office Patient EVOLVE(R) Laser Prostate Treatment
8. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
9. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
10. States First Single Incision Robotic Kidney Removal Performed at Henry Ford Hospital
11. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... New York, NY (PRWEB) , ... May 03, ... ... and NeuroTech NYC , the sensor and data driven conferences, will take ... include:, UnitedHealth's Vidya Raman-Tangella on incorporating technology -- ...
(Date:5/2/2016)... 2, 2016 Q BioMed Inc. ... partner Mannin Research Inc. will be attending the Association ... place from May 1-5, 2016 in Seattle ... with its vendors and research partners. The meeting provides ... and other collaborative opportunities for the MAN-01 program for ...
(Date:4/29/2016)... ... April 29, 2016 , ... Proove ... excited to announce the launch of the Proove Health Foundation . The ... education to promote the use of personalized medicine for tackling the nation’s most-pressing ...
(Date:4/29/2016)... ... ... Intelligent Implant Systems announced today that the two-level components for the Revolution™ Spinal System ... These components expand the capabilities of the system and allow Revolution™ to be utilized ... the company has seen significant sales growth in 1Q 2016, and the system is ...
Breaking Biology Technology:
(Date:3/15/2016)... Yissum Research Development Company of the Hebrew University ... University, announced today the formation of Neteera Technologies ... biological indicators. Neteera Technologies has completed its first round ... Neteera,s ... from sweat ducts, enables reliable and speedy biometric identification, ...
(Date:3/10/2016)... , March 10, 2016 ... market research report "Identity and Access Management Market by ... Compliance, and Governance), by Organization Size, by Deployment, by ... published by MarketsandMarkets, The market is estimated to grow ... Billion by 2020, at a Compound Annual Growth Rate ...
(Date:3/8/2016)... March 8, 2016   Valencell , the ... announced it has secured $11M in Series D ... a new venture fund being launched by UAE-based ... from existing investors TDF Ventures and WSJ Joshua ... continue its triple-digit growth and accelerate its pioneering ...
Breaking Biology News(10 mins):